Corporate Profile
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena’s most advanced drug candidate, lorcaserin, is intended for weight management, including weight loss and maintenance of weight loss, and has completed a pivotal Phase 3 clinical trial program. Arena submitted a New Drug Application for lorcaserin to the FDA in December 2009.Featured Report
2008 Interactive Annual Report
Stock Information
| Ticker | ARNA | Exchange | NASDAQ |
|
|
| Last Price | 3.11 | Change | 0.04 
|
||
| Open | 3.07 | Previous Close | 3.07 | ||
| Day High | 3.15 | Day Low | 3.03 | ||
| 52-Week High | 5.93 | 52-Week Low | 2.26 | ||
|
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|||||
Recent News
Mar 8, 2010
Arena Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Events & Presentations
Mar 10, 2010 at 8:45 AM ET
Cowen and Company 30th Annual Health Care Conference
Mar 12, 2010 at 5:30 AM PT
Q4 2009 Arena Pharmaceuticals Conference Call
View all events & presentations »
Receive Email Alerts
The stock information, SEC filings and press releases included on this website are not provided by Arena Pharmaceuticals, Inc. but by a third-party. Such information is not intended for trading purposes. Arena Pharmaceuticals, Inc. does not guarantee the accuracy or completeness of this information and is not liable in any way whatsoever for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising there from.
